Green Synthesis of Silver Nanoparticles Using Extracts of Ehretia cymosa and Evaluation of Its Antibacterial Activity in Cream and Ointment Drug Delivery Systems

Table 6

The zone of inhibition (mm) obtained with different concentrations of the E. cymosa for the crude extracts and silver nanoparticles loaded ointment formulations.

Drugs tested	% concentration of the active ingredient	Strains of microorganisms used
		S. aureus		E. coli
		Clinical isolates	ATCC 25923	Clinical isolates	ATCC 25922
OB	0	—	—	—	—
ACO1	1	5.4 ± 0.13	5.2 ± 0.15	2.9 ± 0.15	2.8 ± 0.05
ACO2	1.5	6.6 ± 0.09	6.2 ± 0.12	3.0 ± 0.61	2.8 ± 0.30
ACO3	2	7.9 ± 0.21	7.6 ± 0.06	4.2 ± 0.12	4.0 ± 0.22
MCO1	1	7.5 ± 0.33	7.4 ± 0.24	4.6 ± 0.17	4.3 ± 0.10
MCO2	1.5	8.1 ± 0.26	8.0 ± 0.12	6.1 ± 0.30	5.8 ± 0.21
MCO3	2	9.4 ± 0.18	9.2 ± 0.16	7.4 ± 0.08	7.3 ± 0.14
ASO1	1	9.1 ± 0.33	8.9 ± 0.27	6.7 ± 0.42	6.5 ± 0.05
ASO2	1.5	10.4 ± 0.17	10.2 ± 0.35	7.4 ± 0.31	7.3 ± 0.60
ASO3	2	12.2 ± 0.32	12.1 ± 0.21	8.2 ± 0.18	8.1 ± 0.26
MSO1	1	12.6 ± 0.15	12.5 ± 0.53	8.1 ± 0.63	7.9 ± 0.30
MSO2	1.5	13.2 ± 0.22	13.0 ± 0.16	9.5 ± 0.12	9.3 ± 0.34
MSO3	2	14.5 ± 0.62	14.4 ± 0.40	10.3 ± 0.16	10.1 ± 0.10
CO	1	12.5 ± 0.13	12.3 ± 0.08	10.6 ± 0.06	10.2 ± 0.22

Note. OB: ointment base (negative control), ACO1, ACO2, and ACO3: 1%, 1.5%, and 2% aqueous crude extract ointment, respectively, MCO1, MCO2, and MCO3: 1%, 1.5%, and 2% methanol crude extract ointment, respectively, ASO1, ASO2, and ASO3: 1%, 1.5%, and 2% aqueous SNPs ointment, respectively, MSO1, MSO2, and MSO3: 1%, 1.5%, and 2% methanol SNPs ointment, respectively, and CO: 1% ciprofloxacin ointment (positive control).